Skip to main content
Equibles
RARE logo

RARE · Ultragenyx Pharmaceutical Inc. · Analyst Estimates

Track RARE — free

Use RARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.63 +0.33 (+2.02%) At close · Nov 3 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.66B
Shares
98.59M
Volume · Nov 3 3.71M Avg daily vol (3M) 4.25M

Analyst Estimates

Compare analyst forecasts for Ultragenyx Pharmaceutical Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-30 12:29 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-4.96
-4.08
-1.18
6
-4.08
-3.87
-3.85
-4.19
1
2
0
1
Revenue
USD
Publication date not stated
701.90M
760.21M
903.13M
19
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.69
0.23
4.50
6
0.23
0.68
0.67
3.13
0
0
0
3
Revenue
USD
Publication date not stated
764.60M
1.00B
1.64B
19
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.25
-0.75
0.75
6
-0.75
-0.65
-0.58
-0.73
1
1
0
0
Revenue
USD
Publication date not stated
175.00M
183.71M
194.18M
17
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.08
-0.66
0.78
6
-0.66
-0.57
-0.55
-0.71
1
2
0
0
Revenue
USD
Publication date not stated
192.20M
229.66M
360.94M
17
 — — — — — — — —
Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 65 filings 61 filers Visit website Investor relations